Skip to content
Study details
Enrolling now

GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

Medtronic MiniMed, Inc.
NCT IDNCT07228117ClinicalTrials.gov data as of Apr 2026
Target enrollment

400

Study length

about 1 year

Ages

7–85

Locations

28 sites in AR, CA, CO +13

About this study

Researchers are testing the safety of a new insulin pump, called NMX8, when used with a continuous glucose monitoring sensor called Disposable Sensor 5 in people with diabetes. The trial will include adults and children with Type 1 or Type 2 diabetes who are 7-85 years old. Participants will use their current therapy while wearing the DS5 for up to 40 days, logging meals and exercise. Then they will be randomly assigned to one of three groups and given the NMX8 pump to use for 90 days, either bolusing or not bolusing for meals depending on the group.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Use MiniMed™ NMX8-AID System with DS5™

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low15%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Body systems

Endocrinology